What is Immunome Inc Annual Revenue?

Immunome Inc Annual Revenue fell 35.5%, in the last year to $9.04 M. Its sector's average revenue growth for the last fiscal year was 7.54%.

What is Immunome Inc Annual Net Profit?

Immunome Inc Annual Net Profit fell 174.29% in the last year to $292.96 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

What is Immunome Inc Price to Earning Ratio?

Immunome Inc Price to Earning Ratio is -2.35, which is negative.

What is Immunome Inc Stock Price?

Immunome Inc Stock Price fell 48.9% and underperformed its sector by 56.23% in the past year.

What is Immunome Inc Quarterly Revenue?

Immunome Inc Quarterly Revenue fell 28.44% YoY to $2.74 M. Its sector's average revenue growth YoY for the quarter was 5.84%.

What is Immunome Inc Quarterly Net profit?

Immunome Inc Quarterly Net profit rose 13.37% YoY to $80.25 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

What is Immunome Inc Debt to Equity Ratio?

Immunome Inc Debt to Equity Ratio of 0.03 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Immunome Inc Return on Equity(ROE)?

Immunome Inc Return on Equity(ROE) for the last financial year was -194.63%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Immunome Inc Mutual Fund Holding?

Immunome Inc Mutual Fund Holding increased by 3.58% in the last quarter to 43.62.

What is Immunome Inc Institutional Holding?

Immunome Inc Institutional Holding increased by 0.03% in the last quarter to 62.04.

How is the Immunome Inc today?

The Immunome Inc today is trading in the green, up by 10.32% at 7.91.

How has Immunome Inc performed historically?

The Immunome Inc is currently trading up 10.32% on an intraday basis in the past week the index rose 11.41%. The index has been down -20.82% in the past quarter and fell -48.90% in the past year. You can view this in the overview section.

Immunome Inc XNAS: IMNM

Immunome Inc Live Share Price Today, Share Analysis and Chart

Name: Immunome Inc: Is Infosys Ltd. worth buying?
Item: Immunome Inc
Rating: 1.00308325
Author: Trendlyne DVM scores

Download real time

7.91 0.74 (10.32%)

52.94% Fall from 52W High

1.5M XNAS Volume

XNAS 17 Apr, 2025 5:30 PM (EDT)

Immunome Inc Key Metrics

My Metrics

Select

Market Capitalization Below industry Median Unavailable in chosen country	687.8
PE TTM Negative PE TTM Unavailable in chosen country	-2.3
Price to Book Below industry Median Unavailable in chosen country	3.8
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	62
Revenue Growth Qtr YoY % Negative Revenue Growth Qtr YoY % Unavailable in chosen country	-28.4
Operating Revenue growth TTM % Negative Operating Revenue growth TTM % Unavailable in chosen country	-35.5
Net Profit Qtr Growth YoY % Below industry Median Unavailable in chosen country	13.4
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-174.3
Operating Profit Margin Qtr % Negative Operating Profit Margin Qtr % Unavailable in chosen country	-2,030.6
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-1,697.3
Rel Perf vs Sector quarter% Unavailable in chosen country	-19.9
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-194.6
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-150.7

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

6.3 / 100

Technically Bearish

33.8 / 100

1Yr Price target upside is 229%

8 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Immunome Inc Stock Price Analysis

Day Price Range 10.3% 1 Day return Unavailable in chosen country	7.9 (LTP) 78 LowHigh
Week Price Range 11.4% 1 Week return Unavailable in chosen country	7.9 (LTP) 78 LowHigh
Month Price Range -8.7% 1 Month return Unavailable in chosen country	7.9 (LTP) 5.28.7 LowHigh
52 Week Price Range -48.9% 1 Year return Unavailable in chosen country	7.9 (LTP) 5.216.8 LowHigh

View full Share Price History

Immunome Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Inline

Immunome Inc's Revenue was higher than average estimate 1 time in past 2 years

EPS forecast

QUARTER
ANNUAL

Current EPS

-5

Avg. Estimate

-2.7

Low Estimate

-3.9

High Estimate

-1.9

Current EPS

Avg. Estimate

Hit

EPS is expected to grow by 46.2% in FY25

Consensus Recommendation

9 ANALYST Recommendations

STRONG BUY

The consensus recommendation from 9 analysts for Immunome Inc is STRONG BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Immunome Inc Stock Analysis

Immunome Inc stock analysis with key metrics, changes, and trends.

Immunome Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$9.04 M	35.5%	negative	Annual Revenue fell 35.5%, in the last year to $9.04 M. Its sector's average revenue growth for the last fiscal year was 7.54%.
Annual Net Profit	$292.96 M	174.29%	negative	Annual Net Profit fell 174.29% in the last year to $292.96 M. Its sector's average net profit growth for the last fiscal year was -30.36%.
Price to Earning Ratio	-2.35	-	negative	Price to Earning Ratio is -2.35, which is negative.
Stock Price	$7.91	-48.9%	negative	Stock Price fell 48.9% and underperformed its sector by 56.23% in the past year.
Quarterly Revenue	$2.74 M	28.44%	negative	Quarterly Revenue fell 28.44% YoY to $2.74 M. Its sector's average revenue growth YoY for the quarter was 5.84%.
Quarterly Net profit	$80.25 M	13.37%	positive	Quarterly Net profit rose 13.37% YoY to $80.25 M. Its sector's average net profit growth YoY for the quarter was -48.37%.
Debt to Equity Ratio	0.03	-	positive	Debt to Equity Ratio of 0.03 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-194.63 %	-194.63%	negative	Return on Equity(ROE) for the last financial year was -194.63%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	43.62 %	3.58%	positive	Mutual Fund Holding increased by 3.58% in the last quarter to 43.62.
Institutional Holding	62.04 %	0.03%	positive	Institutional Holding increased by 0.03% in the last quarter to 62.04.

VIEW LESS

Loading data..

Immunome Inc - Company Profile

What does Immunome Inc do?

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Gross Remuneration

2024

Gross Remuneration

Year

Immunome Inc Live Share Price Today, Share Analysis and Chart

52.94% Fall from 52W High

Immunome Inc Key Metrics

Market Capitalization

PE TTM

Price to Book

RoA Annual %

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Rel Perf vs Sector quarter%

ROE Annual %

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Immunome Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Immunome Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Immunome Inc's Revenue was higher than average estimate 1 time in past 2 years

EPS forecast

EPS is expected to grow by 46.2% in FY25

Consensus Recommendation

The consensus recommendation from 9 analysts for Immunome Inc is STRONG BUY

Immunome Inc Stock Analysis

Immunome Inc stock analysis with key metrics, changes, and trends.

Annual Revenue fell 35.5%, in the last year to $9.04 M. Its sector's average revenue growth for the last fiscal year was 7.54%.

Annual Net Profit fell 174.29% in the last year to $292.96 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

Price to Earning Ratio is -2.35, which is negative.

Stock Price fell 48.9% and underperformed its sector by 56.23% in the past year.

Quarterly Revenue fell 28.44% YoY to $2.74 M. Its sector's average revenue growth YoY for the quarter was 5.84%.

Quarterly Net profit rose 13.37% YoY to $80.25 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

Debt to Equity Ratio of 0.03 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -194.63%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 3.58% in the last quarter to 43.62.

Institutional Holding increased by 0.03% in the last quarter to 62.04.

Immunome Inc - Company Profile

What does Immunome Inc do?

Immunome Inc Management structure

Mr. Max Rosett

Principal Accounting Officer, Executive Vice President, Operations and Chief Financial Officer

Mr. Robert Lapetina

Vice President, Finance, Corporate Controller and Principal Accounting Officer

Dr. Clay B. Siegall,PhD

Chief Executive Officer, President and Chairman of the Board

Ms. Sandra G. Stoneman

Chief Legal Officer and General Counsel

Mr. Kinney Horn

Chief Business Officer

Dr. Jack Higgins, PhD

Chief Scientific Officer

Immunome Inc Board of directors

Ms. Carol A. Schafer

Director

Dr. Sandra M. Swain, M.D.

Director

Dr. Clay B. Siegall,PhD

Chief Executive Officer, President and Chairman of

Mr. Philip Wagenheim